Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/722723/000072272322000006/hngr-20211231.htm
October 2022
September 2022
September 2022
August 2022
July 2022
July 2022
May 2022
May 2022
February 2022
February 2022
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/722723/000072272322000006/hngr-20211231.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Hanger, Inc..
Hanger, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
In addition, the Amendment changed the definition of EBITDA used in the Net Leverage Ratio and minimum interest coverage ratio to adjust for declines in net revenue attributable to the COVID-19 pandemic.
The decrease in current assets was primarily attributable to a decrease in Cash and cash equivalents of $82.9 million discussed in the "Liquidity" section above and a decrease in Income taxes receivable of $12.3 million, which relates to income tax relief under the CARES Act.
The effective tax rate in 2021 consisted principally of the 21% federal statutory tax rate and non-deductible expenses, offset by research and development tax credits and the release of reserves for uncertain tax positions.
Depreciation expense decreased $1.2 million and amortization expense decreased $1.1 million when compared to the same period in the prior year.
We estimate that approximately 8.3% of this increase related to growth in volume, primarily associated with the recovery from the COVID-19 related impact on 2020 volumes, and the remaining 0.8% related to price growth and improvements in disallowed and patient non-payment rates.
Equipment sales revenue is recognized...Read more
We expect our primary cash...Read more
Sources and Uses of Cash...Read more
The increase in the effective...Read more
Other expenses decreased by $26.3...Read more
Professional fees increased $2.7 million,...Read more
In addition, operating cash flows...Read more
Salary expense decreased $3.2 million...Read more
This was primarily attributable to...Read more
If these assumptions differ from...Read more
Commencing at the start of...Read more
Travel and other expenses decreased...Read more
This was primarily the result...Read more
Therapeutic program equipment and related...Read more
We recognize income related to...Read more
If not paid, the liability...Read more
With these factors in mind,...Read more
Currently, we believe our business...Read more
The decrease in current liabilities...Read more
The first quarter is normally...Read more
These amounts recorded in net...Read more
Cash flows used in financing...Read more
Claims can also be denied...Read more
The decrease in the effective...Read more
These are recorded as a...Read more
The lack of achievement of...Read more
Same clinic revenues decreased $91.9...Read more
Liquidity Outlook and Going Concern...Read more
The increase in inventories, including...Read more
Due to the Omicron variant,...Read more
We believe these assumptions are...Read more
Depreciation expense decreased $2.5 million...Read more
Personnel costs by operating segment...Read more
We do not believe this...Read more
Working capital - As business...Read more
In response to the expected...Read more
Total acquisition-related costs incurred during...Read more
We have earned a reputation...Read more
Sales of consumables are recognized...Read more
These initiatives included: (i) the...Read more
Other expenses increased by $26.4...Read more
Days sales outstanding ("DSO") is...Read more
Effective July 1, 2019, we...Read more
Provisions for product returns and...Read more
Personnel costs in the Products...Read more
We are additionally incurring increased...Read more
We have defined and provided...Read more
Depreciation and amortization for the...Read more
Depreciation and amortization for the...Read more
This was primarily attributable to...Read more
Significant management judgments and assumptions...Read more
The remaining $0.4 million in...Read more
We believe these discontinuances relate...Read more
We believe these discontinuances relate...Read more
Material costs for the year...Read more
Net revenues by operating segment,...Read more
Interest expense for the year...Read more
Interest expense for the year...Read more
CARES Act The CARES Act...Read more
CARES Act The CARES Act...Read more
This decrease in cash used...Read more
These statements are based on...Read more
Same clinic revenue per day...Read more
This has been due to...Read more
As described, we apply judgment...Read more
Medicare and Medicaid regulations and...Read more
During the period April 2020...Read more
The O&P patient care services...Read more
Day-adjusted growth normalizes sales for...Read more
Due to the general fulfillment...Read more
Personnel costs for the year...Read more
Other operating costs for the...Read more
However, due to the risks...Read more
We paid the current portion...Read more
Any impairment would be recognized...Read more
We currently anticipate volumes to...Read more
For the three-month period ending...Read more
Business Environment and Outlook Patient...Read more
Management analyzes sales programs that...Read more
Distribution services revenues are recognized...Read more
In addition, the Amendment contained...Read more
We anticipate that the demand...Read more
General and administrative expenses for...Read more
We allocate any excess purchase...Read more
Goodwill and Other Intangible Assets,...Read more
On average, the cranial device...Read more
During the year, our prosthetics...Read more
The other business in our...Read more
In addition to this capital...Read more
Net revenues for the year...Read more
In the ordinary course of...Read more
Of the $21.9 million in...Read more
Products & Services net revenues...Read more
During 2021 and 2020, we...Read more
During 2021 and 2020, we...Read more
We anticipate that we will...Read more
This was primarily the result...Read more
Overview Business Overview General We...Read more
Prosthetic revenues were 6.1% higher...Read more
As of December 31, 2021,...Read more
We recognized the benefit from...Read more
This decrease in liquidity primarily...Read more
Salary expense increased $7.7 million...Read more
Products & Services net revenues...Read more
The increase compared to the...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Hanger, Inc. provided additional information to their SEC Filing as exhibits
Ticker: HNGR
CIK: 722723
Form Type: 10-K Annual Report
Accession Number: 0000722723-22-000006
Submitted to the SEC: Mon Feb 28 2022 4:16:30 PM EST
Accepted by the SEC: Mon Feb 28 2022
Period: Friday, December 31, 2021
Industry: Specialty Outpatient Facilities